Publications by authors named "Eline Menu"

Claim this Profile
B
B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape.
Arne Van der Vreken, Fien Meeus, Chenggong Tu, Lauren van den Broecke, Vincenzo Raimondi, Eline Menu

J Hematol Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Eline Menu

Mol Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Syntenin inhibition impairs stroma-tumor communication in multiple myeloma and improves bortezomib treatment efficiency.
Chenggong Tu, Raphael Leblanc, Arne Van der Vreken, Marnix Koops, Stephane Audebert, Eline Menu

Hemasphere· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse.
Catharina Muylaert, Lien Ann Van Hemelrijck, Arne Van der Vreken, Robbe Heestermans, Hatice Satilmis, Eline Menu

J Exp Clin Cancer Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy.
Arne Van der Vreken, Fabien Thery, Chenggong Tu, Kevin Mwangi, Sofie Meulewaeter, Eline Menu

J Immunother Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Caveolin-1 in Multiple Myeloma Cells Enhances Chemotherapy and Natural Killer Cell-Mediated Immunotherapy.
Dewen Zhan, Zhimin Du, Shang Zhang, Juanru Huang, Jian Zhang, Eline Menu

Adv Sci (Weinh)· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma.
Dirk Hose, Seemun Ray, Sina Rößler, Ulrich Thormann, Reinhard Schnettler, Eline Menu

J Hematol Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma.
Dirk Hose, Seemun Ray, Sina Rößler, Ulrich Thormann, Reinhard Schnettler, Eline Menu

J Hematol Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies.
Niels Vandewalle, Nathan De Beule, Ann De Becker, Elke De Bruyne, Eline Menu

Exp Hematol Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fueling CARs: metabolic strategies to enhance CAR T-cell therapy.
Arne Van der Vreken, Karin Vanderkerken, Elke De Bruyne, Kim De Veirman, Karine Breckpot, Eline Menu

Exp Hematol Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy.
Yanmeng Wang, Niels Vandewalle, Kim De Veirman, Karin Vanderkerken, Eline Menu

Cell Commun Signal· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia.
Niels Vandewalle, Hatice Satilmis, Emma Verheye, Rong Fan, Yanmeng Wang, Eline Menu

Theranostics· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma.
Yanmeng Wang, Catharina Muylaert, Arne Wyns, Philip Vlummens, Kim De Veirman, Eline Menu

Haematologica· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypoxic Bone Marrow Stromal Cells Secrete miR-140-5p and miR-28-3p That Target SPRED1 to Confer Drug Resistance in Multiple Myeloma.
Hui Zhang, Zhimin Du, Chenggong Tu, Xinyan Zhou, Eline Menu

Cancer Res· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma.
Martina Emde-Rajaratnam, Susanne Beck, Vladimir Benes, Hans Salwender, Uta Bertsch, Eline Menu

Front Immunol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid Leukemia.
Rong Fan, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Elke De Bruyne, Eline Menu

Blood Cancer J· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis.
Arne Van der Vreken, Inge Oudaert, Gamze Ates, Sylvia Faict, Philip Vlummens, Eline Menu

J Pathol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the β -adrenergic receptor increases chemosensitivity in multiple myeloma by induction of apoptosis and modulating cancer cell metabolism.
Hatice Satilmis, Emma Verheye, Philip Vlummens, Inge Oudaert, Niels Vandewalle, Eline Menu

J Pathol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma.
Rong Fan, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Philip Vlummens, Eline Menu

J Immunother Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exosomes in multiple myeloma: from bench to bedside.
Eline Menu, Karin Vanderkerken

Blood· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers.
Rong Fan, Nathan De Beule, Anke Maes, Elke De Bruyne, Eline Menu

Front Immunol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma.
Inge Oudaert, Arne Van der Vreken, Anke Maes, Elke De Bruyne, Kim De Veirman, Eline Menu

Exp Hematol Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?
Catharina Muylaert, Lien Ann Van Hemelrijck, Anke Maes, Kim De Veirman, Eline Menu

Front Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
System Xc inhibition blocks bone marrow-multiple myeloma exosomal crosstalk, thereby countering bortezomib resistance.
Fang Wang, Inge Oudaert, Chenggong Tu, Anke Maes, Arne Van der Vreken, Eline Menu

Cancer Lett· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach.
Philip Vlummens, Stefaan Verhulst, Kim De Veirman, Anke Maes, Eline Menu

Front Cell Dev Biol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis